Grand Medical Group

About us

Grand Medical Group AG is a group of pharmaceutical companies specialized in the development, production, registration and introduction into medical practice of modern innovative products based on organic, synthetic and herbal compounds.

read more

10 Kornmarkt Street, CH - 6004 Luzern, Switzerland

+41 415880810


Each 2 ml ampoule contains 100 mg iron as iron sucrose (iron (III)-hydroxide sucrose complex), ampoules No5


ATC code: B03AC, Anti-anaemic preparation, iron, parenteral preparation Iron sucrose is composed of a polynuclear iron (III)-hydroxide core surrounded by a large number of non-covalently bound sucrose molecules. The complex has a weight average molecular weight (Mw) of approximately 43 kDa. The polynuclear iron core has a structure similar to that of the core of the physiological iron storage protein ferritin. The complex is designed to provide, in a controlled manner, utilisable iron for the iron transport and storage proteins in the body (i.e., transferrin and ferritin, respectively). Following intravenous administration, the polynuclear iron core from the complex is taken up predominantly by the reticuloendothelial system in the liver, spleen, and bone marrow. In a second step, the iron is used for the synthesis of Hb, myoglobin and other iron-containing enzymes, or stored primarily in the liver in the form of ferritin.


MEDEFER is indicated for the treatment of iron de?ciency in the following indications:
• Where there is a clinical need for a rapid iron supply,
• In patients who cannot tolerate oral iron therapy or who are non-compliant,
• In active in?ammatory bowel disease where oral iron preparations are ine?ective,
• In chronic kidney disease when oral iron preparations are less e?ective. The diagnosis of iron de?ciency must be based on appropriate laboratory tests (e.g. Hb, serum ferritin, TSAT, serum iron, etc.).